234 related articles for article (PubMed ID: 31049827)
1. Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.
Chen H; Huang H; Zhao J; Wang Z; Chang M; Xue L; Zhu W; Chai Y; Li G; Wang Z; Wu H
J Neurooncol; 2019 Jul; 143(3):369-379. PubMed ID: 31049827
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.
Chen H; Xue L; Huang H; Wang H; Zhang X; Zhu W; Wang Z; Wang Z; Wu H
EBioMedicine; 2018 Oct; 36():252-265. PubMed ID: 30274821
[TBL] [Abstract][Full Text] [Related]
3. Deletion/duplication mutation screening of TP53 gene in patients with transitional cell carcinoma of urinary bladder using multiplex ligation-dependent probe amplification.
Bazrafshani MR; Nowshadi PA; Shirian S; Daneshbod Y; Nabipour F; Mokhtari M; Hosseini F; Dehghan S; Saeedzadeh A; Mosayebi Z
Cancer Med; 2016 Feb; 5(2):145-52. PubMed ID: 26685928
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
5. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
[TBL] [Abstract][Full Text] [Related]
6. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
[TBL] [Abstract][Full Text] [Related]
7. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
8. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
9. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
10. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
12. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
[TBL] [Abstract][Full Text] [Related]
15. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
[TBL] [Abstract][Full Text] [Related]
16. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
17. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
18. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
Abdel-Fattah R; Challen C; Griffiths TR; Robinson MC; Neal DE; Lunec J
Br J Cancer; 1998 Jun; 77(12):2230-8. PubMed ID: 9649138
[TBL] [Abstract][Full Text] [Related]
19. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
20. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.
Klumb CE; Furtado DR; de Resende LM; Carriço MK; Coelho AM; de Meis E; Maia RC; Rumjanek FD
Eur J Haematol; 2003 Aug; 71(2):81-90. PubMed ID: 12890146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
